Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: HIV protease inhibitors - Medivir/Tibotec

Next Previous
Drug Profile

Research programme: HIV protease inhibitors - Medivir/Tibotec

Alternative Names: HIV-PI therapeutics - Medivir/Tibotec Pharmaceuticals/J&J

Latest Information Update: 04 Nov 2017

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medivir AB
  • Developer Janssen R&D Ireland; Medivir AB
  • Class
  • Mechanism of Action HIV protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported HIV infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in HIV-infections in Sweden
  • 17 Mar 2011 This research programme is ongoing in Sweden
  • 07 Jan 2008 Medivir and Tibotec extend their collaboration for a further year

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top